Selank: Safety Profile & Research Summary
25 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: fevereiro de 2026
Resumo da Pesquisa Pre-clinica
Estudos em Animais
| Modelo | Species | Principais Achados | Ref |
|---|---|---|---|
| Anxiety (UCMS) | Wistar rats | Selank+Diazepam → OA time 8.9× higher do que saline; preveniu stress deterioration | [19] |
| Anxiety Phenotypes | BALB/c vs C57BL/6 mice | Selective anxiolytic in high-anxiety BALB/c; strain-dependent monoamine modulacao | [13] |
| Primate Neurosis | Monkeys | Eliminated fear and aggression; aumentou exploratory activity, long-lasting effect | [2] |
| Alcohol Withdrawal | Outbred rats | ↑ EPM open arms (p<0.01); restaurou mechanical sensitivity; did NOT affect alcohol intake | [16] |
| Morphine Withdrawal | Outbred rats | ↓ withdrawal index 39.6%; ↑ tactile sensitivity 9×; atenuou convulsions (p<0.0001) | [17] |
| Memory Trace | Wistar rats | 30-day memory stability via serotonin metabolismo ativacao | [13] |
| GABAergic Genes | Wistar rats | 45 genes altered at 1h; Gabre ↓20×, Hcrt ↑128× at 3h (explains no sedation) | [9] |
| BDNF Expression | Rats | ↑ Bdnf mRNA at 3h; ↑ BDNF protein at 24h | [12] |
| Gut Microbiota | Wistar rats | Prevented stress-induziu microflora changes; ↓ corticosterone | [18] |
| Influenza (H3N2) | Mice | ↑ survival; IFN-α induction; Th1/Th2 normalization | [14] |
Clinical Studies / Human Data
| Estudo | Desenho | n= | Desfecho Principal | Ref |
|---|---|---|---|---|
| Zozulya 2008 (Phase II) | RCT vs medazepam | 62 | Comparable anxiolytic efficacy to medazepam; + anti-asthenic/psychostimulant effects; onset 1-3 days | [5] |
| Medvedev 2015 (Add-on) | Add-on to Phenazepam | 70 | Earlier onset of benzo effects; diminuiu attention/memory impairment from Phenazepam | [20] |
| Medvedev 2014 (Comparison) | vs Phenazepam | 60 | Pronounced anxiolytic + mild nootropic; effects persist 1 week post-dose | [21] |
| Elderly Vascular Study | Clinical | — | Reduced anxiety, melhorou concentration, aumentou reaction speed in elderly | [3] |
| Uchakina 2008 (Immune) | Immunological | — | Completely suprimiu IL-6 expressao genica in anxious subjects; normalized Th1/Th2 balance | [14] |
Parametros Farmacocineticos
| Parametro | Valor | Ref |
|---|---|---|
| Intranasal Bioavailability | 92.8% (exceptional for a peptide) | [7] |
| Plasma Half-life | ~2 minutes | [7] |
| Duration of Experimental Effects | 20–24 hours (trigger mechanism) | [7] |
| CNS Penetration | Detected in brain within 2 minutes (intranasal) | [7] |
| GABA-A Modulation | Positive allosteric modulator (non-BZD site) | [8] |
| Enkephalinase IC₅₀ | 15–20 μM (human serum) | [10] |
Comparison: Selank vs. Benzodiazepines
| Caracteristica | Selank | Benzodiazepines |
|---|---|---|
| Anxiolytic Effect | Comparable (Phase II) | Established |
| Sedation | None | Common |
| Muscle Relaxation | None | Common |
| Cognitive Impairment | None (nootropic effect) | Amnesia risk |
| Dependence | None observado(a) | High risk |
| Withdrawal | None observado(a) | Significant risk |
| Mechanism | GABA-A PAM + enkephalinase | GABA-A BZD site |
| Additional Effects | Nootropic + immunomodulatory | None |
Comparison: Selank vs. Semax
| Caracteristica | Selank | Semax |
|---|---|---|
| Parent Molecule | Tuftsin (IgG fragment) | ACTH(4-7) |
| Sequence | TKPRPGP (7 aa) | MEHFPGP (7 aa) |
| Primary Focus | Anxiolytic / immunomodulacao | Nootropic / neuroprotecao |
| Unique Mechanism | GABA-A PAM + enkephalinase | MC4/MC5 antagonist + BDNF/TrkB |
| PGP Stabilizer | Yes | Yes |
| Developer | IMG RAS + Zakusov Institute | IMG RAS |
Os produtos oferecidos neste site são fornecidos apenas para estudos in vitro. Estudos in vitro (do latim: em vidro) são realizados fora do corpo. Estes produtos não são medicamentos ou fármacos e não foram aprovados pelo FDA dos EUA para prevenir, tratar ou curar qualquer condição médica, enfermidade ou doença. A introdução corporal de qualquer tipo em humanos ou animais é estritamente proibida por lei.
Apenas para Pesquisa Laboratorial. Não se destina ao uso humano, uso médico, uso diagnóstico ou uso veterinário.
TODOS OS ARTIGOS E INFORMAÇÕES SOBRE PRODUTOS FORNECIDOS NESTE SITE SÃO APENAS PARA FINS INFORMATIVOS E EDUCACIONAIS.
Aviso sobre Estudos In Vitro / Pré-clínicos: Os achados de pesquisa descritos acima foram observados em estudos laboratoriais (in vitro) e/ou em modelos animais. Esses resultados podem não se traduzir em desfechos humanos. Nenhuma alegação é feita em relação a aplicações terapêuticas humanas.
Apenas para Uso Educacional: Este conteúdo é fornecido apenas para fins informativos e educacionais. Não se destina a ser aconselhamento médico e não deve ser utilizado para diagnosticar, tratar, curar ou prevenir qualquer doença ou condição médica. Sempre consulte profissionais de saúde qualificados para decisões médicas.
Editorial Research Note
“Estes produtos não são medicamentos ou fármacos e não foram aprovados pelo FDA dos EUA para prevenir, tratar ou curar qualquer condição médica, enfermidade ou doença.”
Referencias
- Kolomin TA, Shadrina M, Slominsky P, Limborska SA, Myasoedov NF. A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides. Neuroscience & Medicine. 2013;4(4):223–252.
- Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein & Peptide Letters. 2018;25(10):914–923.
- Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of o tratamento of anxiety disorders with selank. Zhurnal Nevrologii i Psikhiatrii. 2015;115(6):33–40.
- U.S. Food and Drug Administration. Substancia Farmaceutica a Granels Used in Compounding Under Section 503B. FDA Compounding Database. 2023.
- Zozulya AA, Neznamov GG, Syunyakov TS, et al. Efficacy and possible mechanisms of action of a novo(a) peptide anxiolytic selank no(a) therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevropatologii i Psikhiatrii. 2008;108(4):38–48.
- Kozlovskii II, Danchev ND. The optimizing action do(a) synthetic peptide Selank on a conditioned ativo(a) avoidance reflex in rats. Neuroscience and Behavioral Physiology. 2003;33(7):639–643.
- Kolomin TA, Agapova T, Agniullin YV, et al. Changes no(a) Transcription Profile do(a) Hippocampus in Response to Administration do(a) Tuftsin Analog Selank. Neuroscience and Behavioral Physiology. 2014;44(8):849–855.
- V'yunova TV, Andreeva LA, Shevchenko KV, et al. Peptide regulacao of specific ligand-receptor interactions of GABA com o(a) plasma membranes of nerve cells. Neurochemical Journal. 2014;8(4):259–264.
- Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31.
- Kost NV, Sokolov OY, Gabaeva MV, et al. Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum. Russian Journal of Bioorganic Chemistry. 2001;27(3):180–183.
- Zozulya AA, Kost NV, Sokolov OY, et al. The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes como um(a) Possible Mechanism of Its Anxiolytic Activity. Bull Exp Biol Med. 2001;131(4):315–317.
- Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of o peptideo Selank regula BDNF expression no(a) rat hippocampus in vivo. Doklady Biological Sciences. 2008;421:241–243.
- Narkevich VB, Kudrin VS, Klodt PM, et al. Effects of Selank on monoamine neurotransmitters no(a) brain of BALB/c and C57BL/6 mice. Bull Exp Biol Med. 2008;145(1):68–71.
- Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii. 2008;108(5):71–75.
- Kozlovskii II, Andreeva LA, Kozlovskaya MM. The role do(a) endogenous opioid system no(a) anxiolytic action of Selank. Bull Exp Biol Med. 2012;153(5):728–730.
- Kolik LG, Nadorova AV, Kozlovskaya MM. Efficacy of Peptide Anxiolytic Selank during Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation. Bull Exp Biol Med. 2014;157(1):61–65.
- Konstantinopolsky MA, Kolik LG, Chernyakova IV. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):730–733.
- Mukhina AY, et al. Effects of Selank on intestinal microbiota and stress-induziu changes. Russian Journal of Physiology. 2019/2020.
- Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017;2017:5091027.
- Kolik LG, Nadorova AV, Antipova TA, Durnev AD. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content. Bull Exp Biol Med. 2019;167(5):641–644.
- Medvedev VE, Tereshchenko ON, Israelian AI, et al. A comparison do(a) anxiolytic effect and tolerability of selank and phenazepam. Zhurnal Nevrologii i Psikhiatrii. 2014;114(7):17–22.
- Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaya MM. Experimental optimization of learning and memory processes by selank. Eksperimental'naia i Klinicheskaia Farmakologiia. 2010;73(8):2–5.
- Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017;8:89.
- Kolomin TA, Shadrina M, Andreeva LA, et al. Expression of inflamacao-related genes in mouse spleen under tuftsin analog Selank. Regulatory Peptides. 2011;170(1-3):18–23.
- Andreeva LA, Nagaev IY, Mezentseva MV, et al. Antiviral properties of structural fragments of o peptideo Selank. Doklady Biological Sciences. 2010;431:79–82.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Ver Pagina Completa de Pesquisa de Selank→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.